876918-34-2

Basic information

• Product Name: 4-Pyridinecarboxylic acid, 2-(3-cyano-4-hydroxyphenyl)-, methyl ester
• CAS NO: 876918-34-2
• Molecular Formula: C14H10N2O3
• Molecular Weight: 254.245
• Mol File: 876918-34-2.mol

Chemical Properties

• CAS DataBase Reference: 4-Pyridinecarboxylic acid, 2-(3-cyano-4-hydroxyphenyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarboxylic acid, 2-(3-cyano-4-hydroxyphenyl)-, methyl ester(876918-34-2)
• EPA Substance Registry System: 4-Pyridinecarboxylic acid, 2-(3-cyano-4-hydroxyphenyl)-, methyl ester(876918-34-2)

Safety Data

• Hazardous Substances Data: 876918-34-2(Hazardous Substances Data)

Upstream product

• 876919-06-1 2-[4-(benzyloxy)-3-cyanophenyl]isonicotinic acid methyl ester 
• 700-12-9 pentamethylbenzene, 
• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 835898-37-8 1-(benzyloxy)-4-bromo-2-cyanobenzene 

Downstream Products

• 876918-46-6 2-(3-cyano-4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)isonicotinic acid methyl ester 
• 934468-60-7 2-[3-cyano-4-(1H-pyrrol-3-yl)phenyl]isonicotinic acid 
• 934470-35-6 methyl 2-[3-cyano-4-(1H-pyrrol-3-yl)phenyl]isonicotinate 
• 934470-34-5 methyl 2-{3-cyano-4-[1-(triisopropylsilyl)-1H-pyrrol-3-yl]phenyl}isonicotinate 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 877033-07-3 2-[3-cyano-4-(cyclobutylmethoxy)phenyl]isonicotinic acid 

Relevant articles and documents

REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER

An object of the present invention is to provide an agent for treating or preventing digestive ulcer that is effective even to ulcer of small intestine and others, for which gastric acid secretion inhibitors such as proton pump inhibitors are ineffective, and is superior to allopurinol in the efficaciousness and the safety. The pharmaceutical composition of the present invention comprising a non-purine xanthine oxidase inhibitor as the active ingredient is useful as an agent for treating or preventing ulcer that forms in digestive tracts by the attack of gastric acid, pepsin, stress, Helicobacter pylori bacteria, NSAID, etc. In particular, it is useful as an ulcer remedy heretofore unknown in the art as it is effective even for ulcer in small intestine for which gastric/duodenal ulcer remedies that inhibit gastric acid secretion such as proton pump inhibitors are ineffective.

TRIARYLCARBOXYLIC ACID DERIVATIVE

It is intended to provide an agent for treating or preventing hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy, diabetic retinopathy and so on which has a non-nucleic acid structure and exerts an excellent xanthine oxidase inhibiting action and a hypouricemic effect. It has been confirmed that a novel triarylcarboxylic acid derivative, which is characterized by having a carboxyl-substituted heteroaryl group and an aromatic ring group such as a phenyl group attached in para-position on a benzene ring and further carrying a cyano group on the same benzene ring, has a potent xanthine oxidase inhibiting action and a hypouricemic effect. Thus, it is found out that this compound is appropriately usable as an agent for treating or preventing hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy, diabetic retinopathy and so on.

2-PHENYLPYRIDINE DERIVATIVE

The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.

2-PHENYLPYRIDINE DERIVATIVE

A 2-phenylpyridine derivative represented by the following general formula (I) or a salt thereof. The compounds have satisfactory xanthine oxidase inhibitory activity and uric acid-lowering activity and are useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory intestinal diseases, diabetic nephropathy, diabetic retinopathy, etc. [The symbols in the formula have the following meanings: R1: H, etc.; R2: -CO2H, etc.; R3 and R4: H, etc.; R5: -CN, etc.; R6: H, etc.; X: -O-, -N(R8)-, or -S-; (provided that the groups represented by R5 and -X-R7 are bonded in a meta position or the para position to the pyridyl group) R8: H, etc.; R7: C1-8 linear or branched alkyl, etc.; Y: a bond, etc.; and R9, R10, and R11: H, etc. (provided that when X is -N(R8)-, then R8 may be bonded to R7 to form a nitrogenous saturated heterocycle in cooperation with the adjacent nitrogen atom).]